Diseases · Entity Annotation Prototype (beta)

1articles mentioning diseases

1disease mentions

1distinct diseases extracted

0%of mentions human-reviewed

Active filtersEntity: gastric or gastro-oesophageal junction (G/GEJ) cancer ×

gastric or gastro-oesophageal junction (G/GEJ) cancer

This disease is selected. Its supporting articles are shown below.

gastric or gastro-oesophageal junction (G/GEJ) cancer1

Articles mentioning gastric or gastro-oesophageal junction (G/GEJ) cancer

1 articles · page 1 of 1

CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial

bmjopen · abstract · 2026-01-09 · 1 matching annotations

86.0%

gastric or gastro-oesophageal junction (G/GEJ) cancer G/GEJ IBI305 sintilimab capecitabine CapeOX oxaliplatin bevacizumab chemotherapy

… been demonstrated to be effective as a first-line treatment of gastric or gastro-oesophageal junction (G/GEJ) cancer. The conventional treatment strategy for patients with advanced…

Browse diseases

gastric or gastro-oesophageal junction (G/GEJ) cancer

Articles mentioning gastric or gastro-oesophageal junction (G/GEJ) cancer

CapeOX (capecitabine and oxaliplatin) combined with sintilimab and bevacizumab biosimilar (IBI305) for first-line treatment of advanced gastric or oesophagogastric junction adenocarcinoma: study protocol for a single-arm, phase Ib/II trial